3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
4
Completed
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Myeloid, Chronic-Phase
2
Bronchiolitis Obliterans Syndrome
2
Recurrence
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Advanced Solid Tumors
1
Interventions
Cyclophosphamide
59
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
55
Busulfan
42
Cyclosporine
39
Mycophenolic Acid
35
Antilymphocyte Serum
34
Filgrastim
32
Tacrolimus
31
Radiotherapy
31
Imatinib Mesylate
28
Whole-Body Irradiation
25
Methotrexate
24
Methylprednisolone
23
Cord Blood Stem Cell Transplantation
18
sargramostim
16
Etoposide
16
Dasatinib
16
Interferon-alpha
15
Cytarabine
15
Melphalan
14
nilotinib
11
Thiotepa
9
Therapeutics
9
Cyclosporins
9
Flow Cytometry
8
Psychiatric Rehabilitation
7
Polymerase Chain Reaction
6
thymoglobulin
5
merphos
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myeloid, Chronic-Phase
×
asciminib
×
Clear all
NCT03874858
2026-04-02
DANTE
Novartis
Phase 2
Completed
124 enrolled
NCT04666259
2025-10-16
AIM4CML
Novartis
Phase 3
Completed
56 enrolled
18 charts